ClinicalTrials.gg
Active, not recruitingNCT06727552Updated Aug 11, 2026

A Study of Barzolvolimab in Patients With Atopic Dermatitis

A Phase 2 interventional study of Barzolvolimab and Matching placebo in Atopic Dermatitis, sponsored by Celldex Therapeutics. Active, not recruiting at 33 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Celldex Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
224th of 544
131 · median 96
Started
2024
with 33 others
Phase 2
202 of 639
18 open now
Primary completion
2026-05
later than 14 of 115 live
Registered
570th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 224th largest by enrollment of the 544 interventional ones that give a count, is one of 34 that started in 2024, is one of 202 in phase 2, reaches primary completion later than 14 of the 115 other live ones, and was the 570th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis

Read the detailed description

This is a multicenter, randomized, double-blind, parallel group, placebo controlled phase 2 study to assess the efficacy and safety of barzolvolimab (CDX-0159) in adult participants with Atopic Dermatitis.

There is a screening period of up to 28 days, a 16-week double-blind, placebo-controlled treatment period, a 16-week double-blind, active treatment period, and a 16-week follow-up period. On Day 1, participants will be randomly assigned on a 1:1:1 ratio to receive barzolvolimab (CDX-0159) by subcutaneous injections of 150 mg every 4 weeks (Q4W) after an initial loading dose of 450 mg [Arm 1], 300 mg Q4W after an initial loading dose of 450 mg [Arm 2], or placebo Q4W [Arm 3]. At Week 16, participants on placebo will be re-randomized on a 1:1 ratio to receive barzolvolimab by subcutaneous injections of 150 mg every 4 weeks (Q4W) after an initial loading dose of 450 mg, 300 mg Q4W after an initial loading dose of 450 mg. Participants on Arms 1 and 2 will undergo a mock re-randomization at Week 16 to maintain the blind.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • AD
  • Atopic Dermatitis
  • eczema
  • barzolvolimab
  • CDX-0159
  • CDX0159-15
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 18 years of age
  2. Diagnosis of chronic atopic dermatitis (AD) for at least 1 year
  3. Onset of symptoms at least 1 year prior and current symptoms consistent with moderate to severe AD as defined by:

    1. EASI ≥ 12 at Visit 1 and EASI ≥ 16 at Visit 2
    2. Body Surface Area of Involvement (BSA) ≥ 10% at Visit 1 and Visit 2
    3. IGA score ≥ 3 at Visit 1 and Visit 2
    4. Severe itch, defined by weekly average of daily PP-NRS score of ≥ 5, during the 7 days prior to treatment
  4. Documented history of inadequate response to treatment with topical medications or for whom topical medications are otherwise medically inadvisable.
  5. Willing and able to complete a daily symptom electronic diary for the duration of the study and adhere to the study visit schedule.

Exclusion criteria

Exclusion Criteria:

  1. Any other active pruritic skin diseases that would confound AD assessments based on the Investigator's clinical judgment.
  2. Phototherapy with ultraviolet (UV) A or UVB within 4 weeks of Visit 1.
  3. Planned or anticipated use of any prohibited medications at any time during the study.
  4. Prior receipt of barzolvolimab or other anti-KIT therapy. There are additional criteria that your study doctor will review with you to confirm you are eligible for the study.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    Barzolvolimab 150 mg

    Barzolvolimab loading dose of 450 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 32 weeks

    Biological: Barzolvolimab

  • Experimental
    Barzolvolimab 300 mg

    Barzolvolimab loading dose of 450 mg subcutaneous injection followed by 300 mg administered every 4 weeks for 32 weeks

    Biological: Barzolvolimab

  • Experimental
    Placebo then barzolvolimab 150 mg

    Placebo subcutaneous injection every 4 weeks for 16 weeks and then barzolvolimab loading dose of 450 mg followed by 150 mg administered every 4 weeks for 16 weeks.

    Biological: Barzolvolimab · Drug: Matching placebo

  • Experimental
    Placebo then barzolvolimab 300 mg

    Placebo subcutaneous injection every 4 weeks for 16 weeks and then barzolvolimab loading dose of 450 mg followed by 300 mg administered every 4 weeks for 16 weeks.

    Biological: Barzolvolimab · Drug: Matching placebo

Interventions

  • BiologicalBarzolvolimab

    Subcutaneous Administration

  • DrugMatching placebo

    Subcutaneous Administration

06

What researchers measure

Primary outcomes

  1. Percent change from Baseline in the weekly average of the daily Peak Pruritus Numerical Rating Scale (PP-NRS) score at Week 16

    Evaluate the clinical efficacy of 2 dose levels (150 mg and 300 mg) of barzolvolimab, compared to placebo, in adult participants with moderate to severe atopic dermatitis (AD) using the PP-NRS. The PP-NRS ranges from 0 = "no itch" to 10 ="worst imaginable itch" for the worst intensity itch in the preceding 24-hr period.

    Time frame: From Day 1 (first dose) to Day 113 (week 16)

Secondary outcomes

  1. Percent change from Baseline in Eczema Area Severity Index (EASI) score at Week 16.

    A total EASI score range from 0 to 72 points will be recorded for each assessment, with higher scores reflecting worse severity of AD. * 0 = clear * 0.1-1.0 = almost clear * 1.1-7.0 = mild * 7.1-21.0 = moderate * 21.1-50.0 = severe * 50.1-72.0 = very severe

    Time frame: From Day 1 (first dose) to Day 113 (week 16)

  2. Proportion of participants achieving an Investigator Global Assessment (IGA) score of "0" or "1" at Week 16.

    The IGA determines severity of AD and clinical response to treatment on a static 5-point scale based on erythema and papulation/infiltration * 0 = Clear * 1 = Almost clear * 2 = Mild * 3 = Moderate * 4 = Severe

    Time frame: From Day 1 (first dose) to Day 113 (week 16)

07

Study locations

33 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in May 2026, 16 months.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 16 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Dec 11, 2024
StartActual
Dec 18, 2024
Primary completionActual
May 6, 2026
CompletionEst.
Dec 2026
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06727552
Responsible party
Sponsor
First posted
Dec 11, 2024
Start date
Dec 18, 2024
Primary completion
May 6, 2026
Completion
Dec 2026 (estimated)
Last update
Aug 11, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Barzolvolimab

Start the discussion